- Home
- CLB vs RGNX Comparison
CLB vs RGNX Comparison
Compare CLB & RGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLB
- RGNX
- Stock Information
- Founded
- CLB 1936
- RGNX 2008
- Country
- CLB United States
- RGNX United States
- Employees
- CLB N/A
- RGNX N/A
- Industry
- CLB
- RGNX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CLB
- RGNX Health Care
- Exchange
- CLB Nasdaq
- RGNX Nasdaq
- Market Cap
- CLB 482.5M
- RGNX 451.1M
- IPO Year
- CLB 1995
- RGNX 2015
- Fundamental
- Price
- CLB $12.49
- RGNX $9.03
- Analyst Decision
- CLB Hold
- RGNX Strong Buy
- Analyst Count
- CLB 2
- RGNX 8
- Target Price
- CLB $12.50
- RGNX $28.50
- AVG Volume (30 Days)
- CLB 501.8K
- RGNX 502.6K
- Earning Date
- CLB 10-22-2025
- RGNX 11-05-2025
- Dividend Yield
- CLB 0.32%
- RGNX N/A
- EPS Growth
- CLB 23.99
- RGNX N/A
- EPS
- CLB 0.62
- RGNX N/A
- Revenue
- CLB $517,378,000.00
- RGNX $155,782,000.00
- Revenue This Year
- CLB N/A
- RGNX $203.27
- Revenue Next Year
- CLB $2.23
- RGNX $0.58
- P/E Ratio
- CLB $20.26
- RGNX N/A
- Revenue Growth
- CLB 0.70
- RGNX 74.95
- 52 Week Low
- CLB $9.72
- RGNX $5.04
- 52 Week High
- CLB $21.83
- RGNX $13.48
- Technical
- Relative Strength Index (RSI)
- CLB 58.33
- RGNX 49.37
- Support Level
- CLB $12.33
- RGNX $8.82
- Resistance Level
- CLB $12.82
- RGNX $10.08
- Average True Range (ATR)
- CLB 0.52
- RGNX 0.54
- MACD
- CLB 0.07
- RGNX -0.05
- Stochastic Oscillator
- CLB 67.42
- RGNX 25.27
About CLB Core Laboratories Inc.
Core Laboratories Inc provides reservoir description and production enhancement services for oil and gas exploration and production. It provides data and analytics to aid well operators in determining optimal methods for recovering, processing, and refining hydrocarbons from a well. It also manufactures the associated lab equipment for its services.
About RGNX REGENXBIO Inc.
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that the Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.